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Abstract
Background: Extrapulmonary small cell carcinomas (ESCC) are rare but aggressive tumors. Relapses are common
despite treatment with chemotherapy and/or radiotherapy. Prospective data for treatment of ESCC are lacking;
treatment of these cancers usually incorporates lung small cell carcinoma treatment recommendations. Cancer
staging remains the most important prognostic factor. Cancer immunotherapy targeting the PD-1/PD-L1 pathway
has shown efficacy in multiple tumor types, and could be an appealing treatment strategy for these rare tumors.
Methods: We investigated PD-L1 expression by immunochemistry (IHC) in ESCCs diagnosed at University of
Massachusetts Medical Center, from 1999 to 2016. 34 cases with sufficient material were selected for PD-L1 IHC
analysis using clone E1L3N. PD-L1 expression was evaluated using the combined positive score (CPS). Retrospective
chart review was performed. We evaluated the incidence and prognostic value of PD-L1 expression in ESCC at our
institution.
Results: Twelve out 34 cases (35%) had PD-L1 CPS scores ≥1. Ten cases had CPS scores ranging 1–5, whereas 2
cases had CPS scores > 80. The overall response rate to the standard chemotherapy with/without radiotherapy in
the PD-L1 positive group was 80% versus 67% for the PDL-1 negative group (p-value 0.67). The median overall
survival for the PD-L1 positive group, regardless of stage, was 11.5 months versus 7 months for PD-L1 negative
group (p-value 0.34). Patients with limited stage disease with positive PD-L1 had a median survival of 53 months
compared to 15 months for patients with PD-L1 negative limited stage (p-value 0.80).
Conclusions: This study showed that at least one third of our ESCC tissue samples expressed PD-L1. There was a
trend for higher response rates to the standard chemotherapy with/without radiotherapy and improved survival in
PD-L1 positive patients. Further studies are required to understand the implications of immune dysregulation in
these aggressive tumors. PD-L1/PD-1 inhibitors should be investigated in this group of patients.
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Background
Extrapulmonary small cell carcinomas (ESCC) have an ag-
gressive nature characterized by early, widespread metasta-
ses. These cancers are rare with a reported incidence of 0.1
to 0.4% in North America and represent up to 5% of all
cases of small cell carcinoma [1]. The median survival for
limited and extensive disease ranges from 1.4 to 3.5 years
and 8 to 12 months, respectively. The overall 5-year sur-
vival rate is less than 15% for limited stage patients [1, 2].
Disease stage, either limited or extensive, remains the
most important prognostic factor for these cancers [3].
Site of origin of ESCC may also impact prognosis. The
most commonly reported primary sites of disease are the
gastrointestinal tract, genitourinary system, and ESCC of
unknown primary tumor [3, 4].
Most treatment recommendations are derived from
small single-institution experiences or extrapolated from
pulmonary small cell cancer as prospective trials are lack-
ing for this disease [5, 6]. Multimodality treatment with
platinum based chemotherapy with radiation and/or sur-
gery is the most commonly used initial treatment approach
for limited stage disease, while platinum based chemother-
apy with etoposide is the most widely used regimen for ex-
tensive stage patients [5–9]. Despite aggressive initial
therapy, most patients with ESCC will relapse with meta-
static disease within a year of initial treatment [5, 6].
Cancer immunotherapy targeting the PD-1/PD-L1 path-
way is not yet established for ESCC. We evaluated the in-
cidence and the prognostic value of PD-L1 expression in
ESCC at our institution. To our knowledge no studies
have investigated the value of PD-L1 testing in ESCC.
Methods
Institutional review board (IRB) approval was obtained.
We investigated PD-L1 expression by immunochemistry
(IHC) in ESCC diagnosed at University of Massachusetts
Medical Center between 1999 and 2016. Forty-five patients
with ESCC were identified. From these patients, 34 had
specimens with sufficient material for PD-L1 IHC analysis.
Specimens included cytology cell blocks, needle core biop-
sies, and whole tissue sections from resection specimens.
Patients included for analysis had a pathologic diagnosis
of ESCC and no evidence of lung disease based on chest
CT scan at time of diagnosis. Pathologic diagnosis included
morphology consistent with small cell carcinoma, and/or
positive immunohistochemical staining with synaptophy-
sin, chromogranin, and/or CD56. Well-differentiated neu-
roendocrine tumors, including carcinoid tumors, were
excluded. Disease stage was classified as extensive (ED) or
limited (LD), using the Veterans’Affairs Lung Study Group
criteria, by reviewing radiologic records [10]. LD was de-
fined as tumor confined to the primary site and regional
lymph nodes. ED was defined as tumor extending beyond
loco-regional boundaries. Chart reviews were conducted to
assess treatment modalities, age at diagnosis, staging, site
of origin, response to treatment, and survival. Response to
treatment was defined as at least partial response, based on
RECIST (Response Evaluation Criteria In Solid Tumors)
criteria [11].
Immunohistochemical studies were performed on 5-um
sections of formalin-fixed, paraffin-embedded tissue.
Slides were first deparaffinized, and rehydrated. Antigen
retrieval was carried out with 0.01 M citrate buffer at
pH 6.0. Slides were heated in a 770-W microwave oven
for 14 min, cooled to room temperature, and rinsed in dis-
tilled water before staining. All the slides were stained on
the Dako Autostainer (Dako Corporation, Carpinteria,
CA). The sections were first blocked for endogenous per-
oxidase activity with an application of Dual Endogenous
Block (Dako) for 10 min, followed by a brief buffer wash.
The slides were then incubated with primary antibody for
30 min. The rabbit monoclonal antibody to PD-L1 (clone
E1L3N, Cell Signaling, #13684) was used at a dilution of
1:500, and diluted with Dako Antibody Diluent (Dako).
Following a buffer rinse, sections were incubated with
Ultraview Detection (Ventana Medical Systems, Tuscon,
AZ) for 30 min. The sections were washed, and treated
with a solution of diaminobenzidine and hydrogen perox-
ide (Dako) for 10 min, to produce the visible brown pig-
ment. After rinsing, a toning solution (DAB Enhancer,
Dako) was used for 2 min to enrich the color. Following
rinsing, the sections were counterstained with hematoxylin,
dehydrated, and cover slipped with permanent media. Sec-
tions of tonsil, placenta, and classical Hodgkin lymphoma
tissue with known positivity for PD-L1 were used as posi-
tive controls for staining.
PD-L1 IHC scoring was performed using the combined
positive score (CPS), previously described for the scoring
of PD-L1 in esophageal adenocarcinoma [12, 13]. CPS is
defined as the total number of PD-L1 positive cells (tumor,
lymphocytes, and macrophages) divided by the total num-
ber of tumor cells. The average CPS of 2 hotspots in each
sample was recorded. Two pathologists independently
reviewed the IHC studies with agreement in most cases
(> 80%), followed by discussion to arrive at a consensus in
the remaining cases. CPS ≥1 was considered positive.
Statistical analysis
All survival and subgroup analyses were performed using
GraphPad Prism software, with curve comparisons per-
formed using log-rank (Mantel-Cox) tests. Kaplan-Meier
survival curves were generated using GraphPad Prism soft-
ware. Response rates to treatment were compared using
Fisher test with p > 0.05 accepted as statistically significant.
Results
Demographic characteristics of the patients and the site
of origin of their cancers are shown in Table 1. The most
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common confirmed primary sites were from the genito-
urinary tract. However, cancers of unknown primary ori-
gin constituted the second most common group.
Twelve specimens (35%) showed positive PD-L1 ex-
pression (CPS ≥1, Fig. 1). Of the positive specimens,
2 showed diffuse PD-L1 expression in both tumor
and stromal cells with CPS > 80. One of these cases
arose from the ureter and the other from the gall
bladder. The other 10 specimens that were considered
positive had CPS scores of 1–5, primarily due to focal
positive staining of non-tumor immune cells adjacent
to the tumor. Twenty-two cases (65%) were negative
for PD-L1 expression (CPS < 1).
All patient with limited stage received a bimodality
treatment with chemoradiation. Fifty-six percent of
extensive stage patients received chemotherapy. One
patient received platinum and irinotecan, while all
other patients with extensive disease who received
chemotherapy were treated with platinum and etopo-
side. The other 46% of patients with extensive stage
disease received only supportive care with no chemo-
therapy; 15% of those patients declined chemother-
apy, 9% expired before obtaining the final pathology
read but received supportive care while in the inten-
sive care unit, and the remainder had very poor
Table 1 Baseline characteristics of ESCC patients
Characteristics Number (%)
Total patients (n) 34
Age
Median 68
Range 20–86
Sex
Male 19 (56%)
Female 15 (44%)
Stage
Limited 11 (32%)
Extensive 23 (68%)
Localization
Genitourinary 18 (53%)
Unknown primary 10 (29%)
Gastrointestinal 5 (15%)
Other (Palate) 1 (3%)
Fig. 1 Examples of extrapulmonary small cell carcinoma stained for PD-L1 expression graded by combined positive score
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performance status with advanced age. Fifteen percent pa-
tients had surgical resection of their primary cancer, in the
setting of a diagnostic evaluation. The overall response
rate in the PD-L1 positive group was 80% versus 67% in
the PD-L1 negative group (p-value 0.67) [Table 2]. The
median overall survival for the PD-L1 positive group, re-
gardless of stage, was 11.5 months versus 7 months for
the PD-L1 negative group (p-value 0.34) [Fig. 2]. Patients
with limited stage disease with positive PD-L1 staining
had a median 53 months overall survival compared to
PD-L1 negative patients with limited disease whose me-
dian overall survival was 15 months (p-value 0.80)
[Table 3]. Extensive stage patients had median overall sur-
vival that was similar between PD-L1 positive and negative
groups, 4 months vs 5 months respectively (p-value 0.50).
Of the 25 patients who relapsed, 14 patients relapsed
after 2007 when the FDA approved Topotecan for re-
lapsed small cell carcinoma of the lung. Two Patients
declined additional chemotherapy, two patients received
Topotecan without any response and the remaining 10
patients progressed rapidly and didn’t get treated due to
poor performance status. None of the patients received
second line chemotherapy before 2007.
Discussion
Our data showed that 35% of ESCC tumor samples
were positive for PD-L1(CPS ≥1). PD-L1 positive
tumors showed a trend toward improved median
overall survival and there was separation of survival
curves between the PD-L1 positive and negative
groups at around 1 year, though not statistically
significant.
Treatment of ESCC tends to follow the treatment plan
utilized for small cell lung cancer. First line treatment
with platinum-based chemotherapy remains the stand-
ard. Second line treatments are lacking for all patients
with small cell carcinomas, regardless of tissue of origin,
with topotecan as the only FDA approved drug in the
second line setting [14]. Immunotherapy is a promising
treatment for small cell carcinomas. PD-L1 inhibitors
have been investigated in small cell lung cancer in a
phase IB study (NCT02054806) as second line therapy.
In that trial, 20 patients with SCLC expressing PD-L1 by
immunohistochemistry were treated with pembrolizu-
mab. Objective responses were observed in seven cases
(35%) [15]. Both nivolumab and ipilimumab have also
demonstrated activity in early-phase clinical studies. In a
phase II study, 216 patients were assigned to treatment
with nivolumab or nivolumab plus ipilimumab at three
different dose combinations. An objective response was
achieved in 10% of patients receiving nivolumab only
versus 21% of patients receiving both nivolumab and ipi-
limumab at any dose combination [16].
PD-1/PD-L1 inhibition has shown efficacy in a variety
of malignancies in both first line and subsequent therapy
[17–19]. Many trials have attempted to identify subsets
of patients who are most likely to benefit from PD-L1
checkpoint inhibition by assessing PD-L1 expression in
tumor specimens and/or tumor microenvironment.
Cancers with high PD-L1 expression have consistently
demonstrated a higher response rate to PD-1/PD-L1
antibodies than cancers that lack PD-L1 expression, al-
though the use of such inhibitors are not limited to the
positive expressers. The use and pitfalls of PD-L1 assays
Table 2 The overall response rate and median survival between
PD-L1 positive and negative groups across all cancer stages
PD-L1 positive
(n = 12)
PD-L1 negative
(n = 22)
P
value
Received treatment 10 (83%) 16 (73%)
Response rates to
treatment
8 (80%) 11 (67%) 0.67
Median overall
survival (mo.)
11.5 7 0.34
0 50 100 150
0
50
100
Survival (months) of ESCC patients with PD-L1 positive 
versus negative staining of tumors
Months
P
er
ce
n
t s
u
rv
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al
PD-L1 negative
PD-L1 positive
Fig. 2 Overall survival (months) of ESCC patients in PD-L1 positive versus negative groups (p 0.34)
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have been reviewed recently [20]. As it remains contro-
versial regarding which scoring system is preferable to
grade the expression, we used the CPS because of the re-
cent trend in using this scoring in other tumors mainly
gastrointestinal [12, 13]. We aimed to provide more in-
formation about the tumor cells and their microenviron-
ment (lymphocytes, and macrophages), for this unstudied
area of such a rare disease.
Tumor PD-L1 status may provide prognostic or pre-
dictive information. A recently published clinical trial
conducted in patients with advanced non-squamous,
non-small-cell lung cancer, demonstrated a higher re-
sponse rate to chemotherapy in patients whose tumors
had high expression of PD-L1 compared to patients
whose tumors failed to express PD-L1 [21, 22]. Similarly,
in our study, ESCC with PD-L1 expression showed
higher response rates to chemotherapy than ESCC that
lacked PD-L1 expression. Additionally, in our study pa-
tients whose tumors tested positive for PD-L1 had im-
proved median overall survival compared with patients
whose tumors did not express PD-L1. The lack of statis-
tical significance in differences of overall survival likely
reflects the small sample size in this single institution re-
view of patients with a rare malignancy. While disease
staging and the site of origin of ESCC remain the most
important prognostic factors, these results suggest that
PD-L1 expression could be a predictive variable for
prognosis and response to chemotherapy in ESCC.
The proposed rational of improved responses in pa-
tients with PD-L1 expression could be related to the
presence of lymphocytes at the microenvironment of the
tumor cells which could be of help to initiate apoptosis
and inflammatory reaction, thus enhancing tumor re-
sponse to chemotherapy and radiation. It is possible that
the enhanced cytotoxicity of combination therapy could
be due to the release of tumor neoantigens from cells
killed by chemotherapy. Combining immunotherapy with
chemotherapy as an upfront treatment is of interest at this
point for all small cell carcinomas as chemotherapy
showed the potential to increase the PD-L1 expression
within the tumor microenvironment, which will enhance
the responses to PD-1 inhibitors [23–25].
Conclusion
In conclusion, this study demonstrates the incidence of
PD-L1 expression in a small cohort of ESCC, and sug-
gests that PD-L1 expression in ESCC may be of prog-
nostic and predictive relevance. Further studies are
required to understand the implications of immune dys-
regulation in these aggressive tumors. PD-L1/PD-1 in-
hibitors should be investigated in this group of patients
given the positive expression of PD-L1 in one third of
patients in our review.
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